Asia Pacific Region to Dominate the Global FMD Vaccines Market

Transparency Market Research has released a new report on the global foot and mouth disease (FMD) vaccines market, which forecasts the growth of the overall FMD vaccines market at a CAGR of 8.8% during the period from 2014 to 2020. The FMD vaccines market was valued at US$0.51 billion in 2013. Due to the increasing frequency of FMD outbreaks, the report projects that the market will reach a worth of US$0.95 billion by the end of 2020. The report is titled ‘Foot and Mouth Disease Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020’.

Browse the full Foot and Mouth Disease Vaccines Market Report at http://www.transparencymarketresearch.com/foot-mouth-disease-vaccines.html

Caused by Aphthovirus, FMD is highly infectious viral disease which affects cloven-hoofed animals and leads to high mortality rate among the young stock such as lambs and piglets. The high prevalence of FMD across the globe affects the international trade in livestock products. The report provides an overview of the overall global FMD vaccines market and evaluates the growth drivers and restraints. Favorable government initiatives to control FMD outbreaks have boosted the growth of the global FMD vaccines market. Also, rising consumption of meat and dairy products demands healthy livestock, which has further fuelled the need for FMD vaccines. The report mentions that the involvement by various governments in purchasing FMD vaccines will lead to the dip in cost which will negatively affect the global FMD vaccines market in terms of revenue. FMD is caused by seven different types of serotype and the current vaccines are serotype-specific. Unpredictable serotype outbreaks can hamper the growth of the global FMD vaccines market. The report indicates that DNA vaccines will open new opportunities for the market during the forecast period.

Depending upon the type of vaccines, the report segments the global FMD vaccines market into conventional vaccines and emergency vaccines. The conventional vaccines have been further categorized into aluminum hydroxide or Saponin based vaccines, and oil-based vaccines. In 2013, oil-based FMD vaccines dominated the global FMD vaccines market with a market share of 63%, owing to its high efficiency and longer effect in treating the disease.

On the basis of application on the livestock, the global FMD vaccines market has been divided into cattle, pigs, sheep and goats, and others. To meet the increasing demand for milk and meat, cattle are reared the most across the globe, owing to which it has emerged as the largest application segment of the global FMD vaccines market. In Middle-east, as pork consumption is prohibited, the cattle segments contribute significantly to the FMD vaccines market of the region. The report predicts that the cattle segment will exhibit the fastest growth during the forecast horizon.

Browse the full Press Release Report:

http://www.transparencymarketresearch.com/pressrelease/foot-mouth-disease-vaccines.htm

Geographically, the global FMD vaccines market has been segmented into four key regions: Europe, North America, Asia Pacific, and Rest of the World. As the disease is non-existent in North America and Europe, the scope of the growth of the vaccines market in these regions is negligible. Due to frequent outbreaks of FMD in Asia Pacific region, the global FMD vaccines market has been dominated by this region with more than 70% share. The report documents the market revenue in China, India, Malaysia, South Korea, and rest of APAC during the forecast period. The report profiles some of the key vendors of the global FMD vaccines market such as Indian Immunologicals Ltd., Bayer AG, Agrovet Co., and Brilliant Bio Pharma Ltd.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=2480

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

North America Spearheading the Global Kidney Cancer Drugs Market

Kidney cancer is considered to be one of the 10 most common cancers affecting men and women across the globe. While the risk of kidney cancer is higher in men than in women, there are numerous factors that determine the risk of cancer. The two main types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC), and kidney cancer drugs are generally administered to patients of stage four, advanced RCC.

Browse Full Global Kidney Cancer Drugs Market Report With Complete TOC @ http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html

According to the American Cancer Society, in the year 2015, approximately 61,560 new cases of kidney cancer will be registered in the United States alone, of which 23,290 will be women and 38,270 will be men. Out of these, around 14,080 people will die from the disease in 2015, of which 5,010 will be women and 9,070 will be men.

The U.S. National Cancer Institute states that kidney cancer is more common among American Indian, African American, and Alaska Native populations. This makes North America a rather large and lucrative market for kidney cancer drugs.

Votrient: Most promising commercially available kidney cancer drug

There are a number of kidney cancer drugs that are prescribed, used, and commercially available today. Some of the major brands are Votrient (Pazopanib), Inlyta (Axitinib), Proleukin (Aldesleukin), Afinitor (Everolimus), Sutent (Sunitinib), Nexavar (Sorafenib), Torisel (Temsirolimus), and Avastin (Bevacizumab).

Of these, Sutent (Sunitinib) dominated the kidney cancer drugs market in 2013, accounting for 30% of the revenue share. Often considered to be the first line of treatment for renal cell carcinoma (RCC), Sutent is one of the most studied kidney cancer drugs for multiple indications. However, owing to its relatively high price, this drug is expected to register a rather meager growth rate of 1.1% from 2012 to 2016 and 2.1% from 2016 to 2020.

Votrient (Pazopanib), on the other hand, is projected to be the most promising kidney cancer drug during the forecast period and will witness the strongest growth between 2012 and 2020. According to a report by Transparency Market Research (TMR), Votrient is estimated to grow at an outstanding CAGR of 41.7% from 2012 to 2016, and 8.9% from 2016 to 2020.

U.S. largest pharmaceutical market in the world

The global kidney cancer drugs market is divided into four key geographic regions: North America, Europe, Asia-Pacific, and Rest of the World. The growing prevalence of kidney cancer makes North America the leading market for kidney cancer drugs; revenue-wise, this region held more than 45% of the total share in 2013. Split into Canada and the United States, the North America market is driven by a growing patient pool, commercial availability of leading drugs for the treatment of kidney cancer, a strong healthcare insurance base, and impressive healthcare systems customized for the pharmaceutical sector. The U.S. accounted for 90% of the North America kidney cancer drugs market.

The APAC region has also proved to be a lucrative market for kidney cancer drugs owing to a rising geriatric population, growing prevalence of kidney cancer, and economic recovery and growth in countries such as China, Japan, Australia, and New Zealand. Registering a 6% growth rate, the Asia-Pacific market for kidney cancer drugs is anticipated to be the fastest growing regional segment during the forecast period.

Market to register healthy growth rate owing to intense competition

The recently-published TMR report has indicated that the market for kidney cancer drugs is characterized by strong competition among industry participants. With the global market being immensely consolidated, there are only a handful of established pharmaceutical companies who dominate the kidney cancer drugs market. Some of the principal players operating in the market are GlaxoSmithKline, plc, F. Hoffmann-La Roche, Ltd., Pfizer, Inc., Bayer AG, and Novartis AG. Among these, Pfizer was the largest maker of kidney cancer drugs in the world and held more than 40% of the total market share in 2013.

The report states that this concentration of power in the hands of a few contributes to the growth of the kidney cancer drugs market. In 2013, the global market was valued at US$2.6 billion and this is estimated to reach US$4.5 billion by 2020, expanding at a compound annual growth rate of 6.6% till 2020.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=537

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Albumin (Excipient) Market Expected to Reach USD 0.8 Billion Globally in 2020

According to a new market report published by Transparency Market Research “Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast, 2014 - 2020,” the global albumin excipient market was valued at USD 704.9 million in 2013 and is expected to grow at a CAGR of 2.3% from 2014 to 2020, to reach an estimated value of USD 828.2 million by 2020.

Selection of appropriate excipients is very important during the development of drug formulations and vaccines. A suitable excipient helps stabilize and protect an active pharmaceutical ingredient (API) in the formulation against degradation, oxidation or aggregation that the API could undergo during manufacturing, transport and storage. As an excipient, albumin has wide applications in drug formulation, drug delivery, vaccine manufacturing and as a component of media for the production of vaccines. Manufacturers are increasingly considering innovative ways to reduce contamination risks of finished products due to the recent incidents of animal virus contamination of biopharmaceutical products. Manufacturers must adhere to strict regulations on the standards and also provide detailed information on the country of origin (BSE free), the types of tissue used and details of the manufacturing process during the compliance and approval procedure.

The global albumin market is analyzed by albumin type, applications and geography. On the basis of type, the market is segmented into human serum albumin, bovine serum albumin and recombinant albumin. Human serum albumin was the largest segment and was valued at USD 476.7 million in 2013. The segment is expected to reach USD 557.0 million in 2020, growing at a CAGR of 2.2% during the forecast period between 2014 and 2020. Bovine serum albumin is used in the production of vaccines such as MMR II, Varivax, Zostavax and RotaTeq in ranges of less than 1 ppm. Extensive research to explore new ways is underway to increase virus yield and quality in manufacturing. Recently, end-user preference has been observed to have shifted towards recombinant human albumin (rAlbumin) used in multiple applications such as in nano formulation and drug carrier over specific therapeutic modalities. Advances in yeast-based protein expression and the successful scale-up have led to the development of an industrial-scale manufacturing process that can produce a highly pure, animal-free rAlbumin suitable for use as an excipient in biotherapeutics.

abumin-market

Primary applications of albumin include drug formulation and drug delivery, vaccines, and component of media. The drug formulation and drug delivery segment is expected to reach USD 395.9 million in 2020. Expansion of the role of albumin in drug delivery has widened the field of nanotechnology as well. For instance, Abraxis BioScience has applied nanotechnology to human serum albumin (HSA) with its nanoparticle albumin-bound, known as ‘NAB’ technology platform. This approach combines HSA with an API for delivering protein drugs.

Geographically, North America continues to dominate the market due to high demand for albumin in drug formulations, and research and development activities. The albumin market in the region was valued at USD 253.8 million in 2013. The current focus of the research community in most of the academic institutions and industry is to use albumin as a carrier for micro- and nanoparticles for sustained-release injectable drugs. Paclitaxel nano-particulate formulation containing albumin as a carrier was approved by the U.S. FDA in September 2013. Countries such as China, India and Australia exhibit significant growth prospects in terms of rapid increase in the research collaboration between industry and research institutions. GlaxoSmithKline Pharmaceuticals Limited (GSK) is funding around USD 4 million per year to initiate research and development program with the leading research institutions in Asia Pacific for the development of potential therapeutics.

Some of the major companies operating in the global albumin market are CSL Behring, HiMedia, InVitria, Mitsubishi Tanabe Pharma, Octapharma AG, Novozymes A/S, Raybiotech, Inc., Sigma-Aldrich Corporation, Thermo Fischer Scientific, Inc. and MedxBio Pte. Ltd. Pharmaceutical companies and research institutes obtain the desired albumin excipient grade from the market players for their development activities. The key players in the global albumin market improve their distribution network by entering into strategic alliances and distributorship agreements. For instance, InVitria partnered with Thermo Fischer Scientific and Sigma-Aldrich in order to provide its customers with product support best tailored to meet their needs. InVitria has distributors across the world including North America, Europe, Asia and Australia.

Browse the full Albumin (Excipient) Market (Types: Human Serum Albumin, Bovine Serum Albumin and Recombinant Albumin; Applications: Drug Formulation and Drug Delivery, Vaccines, and Component of Media) - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast, 2014 - 2020 report at http://www.transparencymarketresearch.com/albumin-market.html

The global albumin market is segmented as follows:

Albumin Market Revenue (USD Million), by Type

Human Serum Albumin

Bovine Serum Albumin

Recombinant Albumin

Albumin Market Revenue (USD Million) and Volume (kg), by Application

Drug Formulation and Drug Delivery

Vaccines

Component of Medium

Albumin Market Revenue (USD Million) and Volume (kg), by Geography

North America

Europe

Asia Pacific

Rest of the World

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=3984

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Human Papillomavirus and Cytomegalovirus Therapeutics Market on the Rise Owing to Alarming Transmission of DNA Viruses among Global Population

Rising incidence of human papillomavirus (HPV) infections in developing as well as underdeveloped economies and increased seroprevalence have respectively driven the global human papillomavirus and cytomegalovirus therapeutics market over recent years, states a recently published report by Transparency Market Research. The report is titled “Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020” and is available for sale on the company website.According to the research report, the global HPV therapeutics market was worth US$1.40 billion in 2013 and is projected to be worth US$2.34 billion in 2020, growing at a 7.7% CAGR during the report’s forecast period of 2014 to 2020. The CMV therapeutics market, on the other hand, stands to grow from US$0.87 billion in 2013 to US$0.92 billion in 2020 at a meager CAGR of 1.5% between 2014 and 2020.

The HPV therapeutics market is segmented on the basis of drug class, application, and pipeline drugs. In terms of revenue, immunomodulators were the dominant drug class in 2013 owing to cost-effectiveness, increased efficiency, and its nature as a non-invasive treatment. Application-wise, the segment of genital warts held the largest share of the HPV therapeutics market that year.Application, antiviral drugs, and pipeline drugs are the criteria based on which the CMV therapeutics market is segmented. Among the major antiviral drugs, ganciclovir and valganciclovir held the largest share of the CMV therapeutics market in 2013, while retinitis was the biggest application segment of the CMV therapeutics market that year.

The global HPV and CMV therapeutics market is segmented into five major regions: North America, South America, Europe, Asia Pacific, and Rest of the World. North America led the global HPV and CMV therapeutics market in 2013 in term of revenue. The HPV market in the region is driven by a rise in the sexually active population, increase in diagnostic rate, and growing international migration. The CMV therapeutics market in North America is fueled by increasing cost of drugs, rise in organ transplant surgeries, and high risk of STDs. The South America and Asia Pacific region are both estimated to witness significant growth in the HPV and CMV therapeutics market by 2020.

Browse the full Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 report at http://www.transparencymarketresearch.com/hpv-cmv-therapeutics-market.html

Clinigen Group plc, Perrigo Company plc, Roche Holdings AG, Merck & Co., Inc., AbbVie, Inc., Actavis plc, and Valeant Pharmaceuticals International, Inc. are the companies profiled in the HPV and CMV therapeutics market report. The CMV therapeutics market was dominated by Roche AG in 2013, thanks to Valcyte being the sole branded formulation available in the market. The HPV therapeutics market was led by Valeant Pharmaceuticals in 2013, owing to the success of its leading brands Aldara, Zyclara, Efudex, and Carac.Each of the players featured in this report are profiled based on attributes such as company and financial overview, product portfolio, recent developments, and business strategies such as mergers and acquisitions, geographic expansions, R&D practices, collaborations and agreements, and product launches.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=3986

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Rising Preference for Generic Drug Variants to Negatively Impact Global Kidney Cancer Drugs Market

According to the latest research report released by Transparency Market Research, the global kidney cancer drugs market is expected to grow consistently at a CAGR of 6.6% during the period between 2014 and 2020. The report titled “Kidney Cancer Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” forecasts that in 2013, the global kidney cancer drugs market was worth US$2.6 billion and with consistent growth, the market will be valued at US$4.5 billion by 2020.

Browse the full Kidney Cancer Drugs Market report at

http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html

According to the World Cancer Research Fund International, kidney cancer is the twelfth most common cancer in the world. Also known as Renal Cell Carcinoma (RCC), it is associated with smoking, obesity, and reduced physical activity. The report mentions that the rise in the reported cases of kidney cancer worldwide along with rising geriatric population will fuel the growth of the global kidney cancer drugs market. The report cites that the growth of the global kidney cancer drugs market will get fuelled by the approval and commercialization of novel molecules in treating kidney cancer. However, the high cost of the drugs will deter the growth of the global kidney cancer drugs market. The report predicts that the increasing preference of generic drug variants will negatively impact the global kidney cancer drugs market.

The report studies the global kidney cancer drugs market depending upon the major branded drug used by the patients. Votrient, Inlyta, Avastin, Torisel, Proleukin, Afinitor, Sutent, and Nexavar are the major branded drug segments of the global kidney cancer drugs market. In 2013, Sutent dominated the global kidney cancer drugs market with more than 30% of the market share. Sunitinib (marketed as Sutent by the drug-manufacturing giant Pfizer) has been often used as the first-line treatment for renal cell carcinoma. The report suggests that the high price of the drug is expected to slow down the growth of this drug segment and the segment will reflect a sluggish growth at 1.1% from 2012 to 2016 and at 2.1% CAGR from 2016 to 2020. Votrient is predicted to be the fastest growing segment of the global kidney cancer drugs market. It is projected to take a leap at 41.7% CAGR during the period between 2012 and 2016. The growth of this segment will slow down considerably from 2016 to 2020 to a CAGR of 8.9%.

The report segments the global kidney cancer drugs market on the basis of the potential pipeline drugs to be launched during the forecast horizon. Cabozantinib, AGS-003, Dovitinib, Opdivo, and Keytruda are some of the drugs expected to be launched and commercialized during the period between 2012 and 2016, thereby strengthening the overall global kidney cancer drugs market.

Browse the full Press Release Report:

http://www.transparencymarketresearch.com/pressrelease/kidney-cancer-drugs-market.htm

Geographically, the report segments the global kidney cancer drugs market into four key regions: North America, Asia Pacific, Europe, and Rest of the World. North America was the largest region of the global kidney cancer drugs market, accounting for more than 45% share. Due to the U.S. being the largest pharmaceutical market worldwide, the overall cancer drugs market receives the highest revenue for each of the drug segments from the country. The U.S. accounts for more than 90% of the global kidney cancer drugs market in North America, followed by Canada, which fills up the remaining market share in the region. The report mentions that the kidney cancer drugs market in Asia Pacific region will grow at a CAGR of 6% due to the rising demand from countries such as Australia, Japan, New Zealand, and China.

The global kidney cancer drugs market is highly consolidated with GlaxoSmithKline, Novartis AG, and Pfizer Inc. being some of the key players. Pfizer dominated more than 40% of the global kidney cancer drugs market in 2013.

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=537

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Transparency Market Research Projects U.S. Vaccine Market to be Valued at USD 17.4 billion by 2018

Data from a new report published by Transparency Market Research “U.S. Vaccine Market - U.S. Industry Analysis, Size, Share, Growth, And Forecast, 2012 - 2018", estimates the U.S. vaccine market to be worth USD 12.8 billion in 2012 and further expected to reach USD 17.4 billion by 2018, growing at a CAGR of 5.3% from 2012 to 2018.

Browse Full U.S. Vaccine Market Research Report With Complete TOC @ http://www.transparencymarketresearch.com/us-vaccine-market.html

Vaccines for different disorders and illnesses are included among the leading earners in the pharmaceutical industry. Over the recent years, enhanced research and development in this market has led to the production of better-quality and effective drugs and vaccines to treat various illnesses. The vaccine sales in U.S. are growing rapidly at a faster rate as compared to the other prescription medicines in the market. U.S. has showed a substantial revenue growth in the vaccine production market increasing the enormity of this industry as well.

The vaccine sales are chiefly resistive to the generic competition that is quoting drug makers billions of dollars in revenues on each of their top-selling vaccine treatments. Moreover, government supporting agencies are unfailing buyers of the vaccine products both in the U.S., as well as across the globe. Hence, U.S. is focused on continuing to lead the global vaccine market amongst other markets in the world. This drive is also due to the rising prevalence of infectious diseases in animals and humans, and improvements seen in the biotechnology sector across U.S.

According to the industry best market research firms’ surveys, many U.S. pediatricians claimed that over half of the U.S. population have parental concerns about general vaccines and child immunization. It is for such reasons, pediatric vaccine segment in the U.S. human vaccine market takes pride in holding the highest market share, as well as high growth rate because of government compulsion for child immunization. The adult & adolescent vaccine market in the

U.S. is expected to grow judiciously over the next six years due to increasing awareness for human papillomavirus (HPV) and other viral diseases.

On the other hand, the livestock vaccine is another leading segment across the U.S. Due to an increased awareness towards protecting infectious diseases in cattle, rising vaccination to prevent breeding animals against illnesses and disorders, and organizing the entire dairy sector, this market accounted for 58.1% of the total shares in 2012. The Bovine vaccine sector in the United States is considered to be the largest revenue generating sector in the present day.

Browse Full Press Release Report:

http://www.transparencymarketresearch.com/pressrelease/us-vaccine-market.htm

However, in 2011, the feline vaccine and canine vaccine also accounted for approximately 95.1% shares in the overall U.S. companion animal vaccine market.

This report includes more information about the generalized overview of the U.S. vaccine market including definitions, applications, and global market industry structure. It discusses the ephemeral shelf-life of certain vaccines available in the market and how they will have a negative impact on the overall market size and growth. However, the report also includes the market analysis of the overall vaccine industry that has multinational firms working on huge product pipeline in order to overcome all the shortcomings and restraints. The report provides extensive analysis of the U.S. vaccine market and the factors that will further revolutionize this industry towards a massive growth.

Among all the geographical regions, U.S. Vaccine Market is considered to be the largest in the history of vaccine. Since 2011, there have been some significant leading producers of human vaccine for the U.S. market and the names included are Merck, Sanofi-Aventis, Pfizer, GlaxoSmithKline, Sanofi-Pasture and Novartis. Similarly, for the animal vaccine market, the leading producers of animal vaccine for the U.S. market includes Merial (Sanofi-Aventis), Pfizer Animal Health, Novartis Animal Health, and Intervet/Schering-Plough (Merck).

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=553

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

U.S., Europe and Japan Orthopedic Soft Tissue Surgical Procedures Market Expected to Reach USD 10.2 Billion in 2020

According to a new market report published by Transparency Market Research “U.S., Europe and Japan Orthopedic Soft Tissue Surgical Procedures Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” the U.S., Europe and Japan orthopedic soft tissue surgical procedures market was valued at USD 7.3 billion in 2013 and is estimated to reach a market worth of USD 10.2 billion in 2020 growing at a CAGR of 4.9% from 2014 to 2020.

Browse the full U.S., Europe and Japan Orthopedic Soft Tissue Surgical Procedures Market report at http://www.transparencymarketresearch.com/soft-tissue-repair-sports-medicine.html

The report on U.S., Europe and Japan orthopedic soft tissue surgical procedures market studies market size of rotator cuff repair, vaginal prolapse, lateral epicondylitis, achilles tendinosis repair, gluteal tendon repair and anterior cruciate ligament reconstruction (ACL). Rising number of sport related injuries coupled with growth of active aging population in the developed regions would boost the demand of orthopedic soft tissue surgeries. According to the American Academy of Orthopaedic Surgeons (AAOS) and the American Orthopaedic Society for Sports Medicine, over 150,000 anterior cruciate ligament (ACL) injuries occur each year in the U.S. alone. Additionally, introduction of high cost and innovative surgical repair products and increasing incidence of obesity have raised the demand of orthopedic surgeries thereby propelling market growth. For example, Biomet, Inc. launched JuggerKnotless Soft Anchor device in July 2014 which featured company’s all-suture anchor technology. This device enables the repair of rotator cuff damage with better restoration and high efficacy. Growing acceptance of minimally invasive soft tissue surgical techniques (arthroscopy procedures) has enabled the completion of soft tissue surgeries in shorter time with lesser complication rates. This factor is also increasing the uptake of soft tissue surgeries. However, asymptomatic nature of soft tissue surgeries and high threat from conservative therapy are anticipated to restrain the market growth.

In terms of various surgical procedures ACL reconstruction accounted for the largest share of the market in 2013. ACL reconstruction is also likely to retain its dominant position in the future as it is the most common knee injury that requires surgical intervention. Rising participation in sports such as football, basketball and others along with increasing number of patients opting for reconstructive surgeries due to introduction of minimally invasive surgeries would fuel the growth of this segment. Similarly, launch of bio-absorbable which nullifies the risk related to implant removal would also aid in increasing the market size for ACL reconstruction. The market of gluteal tendon repair accounted for the smallest share in 2013 owing to large pool of patients being treated by non-operative methods such as pain killers and steroid injection for this condition.

Browse the full Press Release Report:

http://www.transparencymarketresearch.com/pressrelease/us-soft-tissue-repair-sports-medicine.htm

soft-tissue-repair-sports-medicine-market

Geographically, the U.S. orthopedic soft tissue surgical procedures market captured major market revenue in 2013 and is expected to dominate the market during the forecast period from 2014 to 2020. Rising population base, increasing urge to stay healthy among geriatric population and improving healthcare coverage would contribute towards the growth of orthopedic soft tissue surgical procedures in this region. The orthopedic soft tissue surgical procedures market in Europe is anticipated to grow at a CAGR of 4.7% due to increasing number of sports related injuries. According to “Injuries in the European Union” published by EuroSafe, sports related injuries accounted for around 14% of the total injuries in the European Union. Similarly, a survey conducted by the professionals in Europe in 2010 concluded that the annual prevalence of people consulting for shoulder pain was 2.4% in the U.K.; most of these were attributed to rotator cuff injuries. Thus, increasing incidences of soft tissue injuries would propel the market growth in this region.

The orthopedic soft tissue surgical procedures market is fragmented in nature and is dominated by players, namely Arthrex, Inc., Smith & Nephew, plc., DePuy Synthes, Inc., Stryker Corporation., CONMED Corporation, and ArthroCare Corporation. Of all these, Arthrex was identified as the largest player in this market in 2013 followed by Smith & Nephew and Depuy Synthes, Inc.

The U.S., Europe and Japan orthopedic soft tissue surgical procedures market is segmented as follows:

U.S. Orthopedic Soft Tissue Surgical Procedures Market, by Indications

Rotator Cuff Repair

Vaginal Prolapse

Lateral Epicondylitis

Achilles Tendinosis Repair

Gluteal Tendon Repair

Anterior Cruciate Ligament (ACL) Reconstruction

Europe Orthopedic Soft Tissue Surgical Procedures Market, by Indications

Rotator Cuff Repair

Vaginal Prolapse

Lateral Epicondylitis

Achilles Tendinosis Repair

Gluteal Tendon Repair

Anterior Cruciate Ligament (ACL) Reconstruction

Japan Orthopedic Soft Tissue Surgical Procedures Market, by Indications

Rotator Cuff Repair

Vaginal Prolapse

Lateral Epicondylitis

Achilles Tendinosis Repair

Gluteal Tendon Repair

Anterior Cruciate Ligament (ACL) Reconstruction

Request a Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1768

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.